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Background: A single platform designed for the synchronous screen-
ing of multiple mutations can potentially enable molecular profiling 
in samples of limited tumor tissue. This approach is ideal for the 
assessment of advanced non–small-cell lung cancer (NSCLC) diag-
nostic specimens, which often comprise small biopsies. Therefore, 
we aimed in this study to validate the mass spectrometry-based 
Sequenom LungCarta panel and MassARRAY platform using DNA 
extracted from a single 5 μM formalin-fixed paraffin-embedded tis-
sue section.
Methods: Mutations, including those with an equivocal spectrum, 
detected in 90 cases of NSCLC (72 lung biopsies, 13 metastatic tissue 
biopsies, three resections, and two cytology samples) were validated 
by a combination of standard sequencing techniques, immunohisto-
chemical staining for p53 protein, and next-generation sequencing 
with the TruSight Tumor panel.
Results: Fifty-five mutations were diagnosed in 47 cases (52%) in 
the following genes: TP53 (22), KRAS (15), EGFR (5), MET (3), 
PIK3CA (3), STK11 (2), NRF-2 (2), EPHA5 (1), EPHA3 (1), and 
MAP2K1 (1). Of the 90 samples, one failed testing due to poor 
quality DNA. An additional 7 TP53 mutations were detected by next-
generation sequencing, which facilitated the interpretation of p53 
immunohistochemistry but required 5 × 10 μM tumor sections per 
sample tested.
Conclusions: The LungCarta panel is a sensitive method of screen-
ing for multiple alterations (214 mutations across 26 genes) and 
which optimizes the use of limited amounts of tumor DNA isolated 
from small specimens.
Key Words: Non–small-cell lung cancer, Mutation, Mass spectrom-
etry, Biopsy.
(J Thorac Oncol. 2015;10: 784–792)
Non–small-cell lung cancer (NSCLC), a disease which accounts for over 85% of all lung cancer cases,1 is cur-
rently evolving into a collection of molecular subtypes with 
individual “personalized” therapies2 and clinicopathologi-
cal associations. Increases in progression-free survival of 
more than 4 months, compared with standard chemotherapy 
regimens, have been observed after treatment with epider-
mal growth factor receptor (EGFR) or anaplastic lymphoma 
kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients 
harboring the appropriate activating mutation or transloca-
tion.3–5 Consequently, screening for these alterations is becom-
ing an established component of routine diagnostic practice 
worldwide. There are, however, a multitude of other targets6 
emerging in both adenocarcinoma (ADC) and squamous cell 
carcinoma (SCC), the two main subtypes of NSCLC, and the 
possibility of exploiting alterations, including those in the 
MAP2K7,8 and mTOR9,10 pathways has led to the development 
of comprehensive assays designed to detect multiple muta-
tions in different genes.
The majority of NSCLC cases present at a late stage 
with an associated poor prognosis.11 As a result up to 70% 
of lung tumors are sampled and staged either by cytological 
specimens (such as fluids or lymph node aspirates) or by small 
tissue biopsies and not by resection samples.12 These speci-
mens will often have a lower percentage of cancer cells and 
due to the small biopsy volume a limited number of sections 
available for genetic testing. Therefore, the introduction of 
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high throughput platforms with the capacity to screen mul-
tiple mutations from DNA derived from a single section will 
have a significant impact on diagnostic screening. Although 
next-generation sequencing (NGS) can potentially screen 
for an expanded array of mutations, copy number alterations 
and translocations, the diagnostic yield is often restricted 
by the need for a relatively high neoplastic cell content 
(NCC) required to give an optimal DNA quality and quan-
tity. Currently, this can often only be obtained from a resec-
tion specimen. In this study, we aimed to evaluate the mass 
spectrometry-based LungCarta panel on a series of NSCLC 
samples which comprised mainly small biopsies from patients 
with (mostly) advanced stage disease.
PATIENTS AND METHODS
Patients and Tissue Specimens
Ninety samples comprising formalin-fixed paraffin-
embedded tissue (FFPET) biopsies and cytology specimens, 
with accompanying reports, were reviewed from patients diag-
nosed with NSCLC in Greater Manchester, UK over a period 
extending from 2008 to 2012. Samples were fixed in 10% neu-
tral-buffered formalin for a period of 12 to 24 hours. Tumor 
morphology (based on a haematoxylin and eosin stain) was 
reviewed by two pathologists, (A.M.Q. and D.N.). ADCs and 
SCCs were diagnosed according to established respective cri-
teria of glandular differentiation or keratinization.12–14 Tumors 
with definite ADC or SCC features were classified on morphol-
ogy alone, (58 cases) and the remaining 32 cases were catego-
rized based on thyroid transcription factor-1 (TTF-1) and p40 
immunohistochemical staining. Tumors that were TTF-1 posi-
tive and p40 negative were classified as ADC, whereas those 
that were p40-positive and TTF-1 negative were diagnosed as 
SCC. Any tumors that were negative for both stains were clas-
sified as NSCLC not otherwise specified (NOS; there were 
no cases with positivity for both stains). The NCC of each 
sample was determined based on the number of tumor nuclei 
relative to nuclei of inflammatory cells and stromal cells, and 
categorized as less than 10%, 10–20%, 20–30%, 30–50%, or 
more than 50%. Any samples with less than 20% NCC were 
macrodissected to increase the final NCC to at least 10%. 
The tissue surface areas ranged from 2 to 300 mm2 (median 
12 mm2). This study was approved by the North West Research 
Ethics Committee (National Research Ethics Service), refer-
ence numbers 07/H1014/96 and 09/H1011/55. All molecular 
and immunohistochemical tests were conducted in accredited 
clinical genetics and pathology laboratories.
Mutation Profiling and Confirmation
Screening for mutations was performed with the 
LungCarta Panel (Sequenom, San Diego, CA), which enables 
the detection of 214 mutations across 26 genes (AKT1, ALK, 
BRAF, DDR2, EGFR, EPHA3, EPHA5, ERBB2, FGFR4, JAK2, 
KRAS, MAP2K1, MET, NOTCH1, NRAS, NRF2, NTRK1, 
NTRK2, NTRK3, PIK3CA, PTCH1, PTEN, PTPN11, PTPRD, 
STK11, TP53). In each case, DNA was extracted manually from 
one 5 μM FFPET section or curl using the cobas DNA Sample 
Preparation Kit. For cytology samples, the DNA was extracted 
from one 5 μM section of paraffin-embedded cell block prepa-
rations. DNA concentrations were assessed by optical density 
measurement on a NanoDrop spectrophotometer, and ranged 
from 0.55 to 112 ng/μl (median 7.31 ng/μl). Mutation profil-
ing was conducted using the Sequenom MassARRAY plat-
form, which utilizes multiplexed polymerase chain reaction 
(PCR) single base extension reactions (iPLEX chemistry)15 
and matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry.16–18 The LungCarta assay had previously 
been validated on the Sequenom platform using known muta-
tion positive control samples, previously characterized on 
other platforms, e.g., KRAS mutation on Pyrosequencing. This 
allowed us to set the threshold levels for confident assignment 
of mutations. Equivocal mutations were defined as spectral 
alterations detected which were of uncertain significance. 
Mutations were detected using DNA quantities, which ranged 
from 28.6 to 5850 ng (median 380.1 ng).
Mutations identified using LungCarta were confirmed 
by various methods including Sanger sequencing, pyrose-
quencing, the cobas EGFR Mutation Test, NGS (TruSight 
Tumor panel, Illumina, San Diego, CA),19,20 or retesting by the 
LungCarta assay (Fig 1). NGS with the TruSight Tumor panel 
was also used to screen for the presence of TP53 mutations in 
samples which were wild-type for TP53 alterations detected 
FIGURE 1.  Flowchart of mutations detected by LungCarta 
panel including the confirmations of all those with definite 
mutant allele spectra and those which appeared equivocal 
due to low allele frequency (less than 10%) or a poor quality 
spectrum. Samples with TP53 mutations were also con-
firmed by p53 immunohistochemistry. One sample failed the 
LungCarta assay due to poor quality DNA and low cancer cell 
content. Six mutations (see text), accounting for 11% of 55 
mutations finally reported, were present on the initial assay 
and were not confirmed on repeat screening by LungCarta 
due to a low amplification yield or equivocal spectra.
786 Copyright © 2015 by the International Association for the Study of Lung Cancer
Quinn et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 5, May 2015
by the LungCarta panel and which had p53 protein expression 
detected by immunohistochemistry (IHC). The TruSight panel 
screens 82 exons in 26 genes across 175 amplicons (AKT1, 
ALK, APC, BRAF, CDH1, CTNNB1, EGFR, ERBB2, FBXW7, 
FGFR2, FOXL2, GNAQ, GNAS, KIT, KRAS, MAP2K1, MET, 
MSH6, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SRC, 
STK11, TP53), including complete coverage of greater than 
85% of exon coding sequence and total coverage of the coding 
sequence of selected genes such as TP53. For the TruSight panel 
DNA was extracted from 5 × 10 μM sections of selected cases 
using the Qiagen FFPET kit followed by a qPCR-based assay 
to quality assess the extracted material for further processing. 
An extension and ligation-based amplicon library preparation 
assay specific for each of the two strands of DNA was used for 
all targets and the index sequence was incorporated into the 
tailed universal PCR primers to identify the sample. The result-
ing two independent libraries were combined for sequencing. 
NGS was carried out using Illumina MiSeq21 (San Diego, CA) 
with a minimum read depth of at least 1000× combined cover-
age between the two libraries targeted for all amplicons. The 
information from both strands was used to demultiplex and 
align the reads and calculate variant frequencies.19
Immunohistochemistry
All IHC was conducted on 5 μM FFPET sections. 
Appropriate positive and negative controls were included with 
the study sections. Diagnostic IHC stains (TTF-1 and p40) were 
carried out on 3 μM sections from a total of 32 cases, where the 
morphology based on review of the H&E stain was inconclu-
sive. Antibody incubations and detection were carried out on a 
Menarini IntelliPATH FLX (A. Menarini Diagnostics, Winnersh-
Wokingham, Berkshire, UK) using TTF-1 (mouse monoclonal 
8G7G3/1, 1:200, Dako, Glostrup, Denmark) or ΔNp63 (rab-
bit polyclonal p40, 1:200, Calbiochem, Nottingham, UK) as 
described previously.22 TTF-1 and p40 staining was nuclear.
Immunohistochemical staining for ALK protein was car-
ried out on a section from each ADC and NOS case (46 cases 
in total). Antigen retrieval was performed by heating slides 
for 30 minutes at 100°C in Bond Epitope Retrieval Solution 2 
(Leica Microsystems, Milton Keynes, UK), followed by a per-
oxidase blocking step for 5 minutes. The sections were then 
incubated with anti-ALK antibody (clone 5A4, Novocastra 
1:25). Sections were stained with the Leica BOND-MAX 
autostainer (Leica Microsystems), Bond Polymer Refine 
Detection kit (Leica) and Leica Microsystems reagents, and 
were assessed for cytoplasmic staining.
Staining for p53 protein was carried out using a mouse 
monoclonal antibody (clone DO-7, Dako, 1:50) on 19 of 20 
cases with a TP53 mutation detected by LungCarta screening 
(one case with a TP53 mutation did not have available tissue). 
The p53 staining was nuclear, and was also conducted on 10 
cases wild-type for TP53 by LungCarta screening. Sections 
were stained with the automated Ventana BenchMark XT IHC 
⁄ ISH Staining Module (Ventana Co., Tucson, AZ) as described 
previously.23 H scores ranging from 0 to 300 were calculated 
as intensity × %tumor area stained (area of tumor stained × 
intensity score 1+) + (area of tumor stained × intensity score 
2+) + (area of tumor stained × intensity score 3+).24
Statistical Analysis
Kaplan–Meier survival curves were conducted with 
MedCalc version 11.4.40 (Mariakerke, Belgium). The curves 
were compared using the log rank test. The χ2 test was used 
to analyze the relation between categorical variables and the 
Student t test was used for continuous variables. All p values 
were two-sided and a p value less than 0.05 was considered 
significant.
RESULTS
Patient Characteristics
A summary of clinical and pathological characteristics 
is provided in Table 1. A total of 90 cases which included 72 
lung biopsies, three resections, 13 metastatic tissue samples, 
and two cytology specimens were reviewed and classified 
as 40 ADC, 44 SCCs, and six NSCLC NOS. All ADC and 
NOS cases with adequate tissue were screened for ALK pro-
tein expression by IHC. A total of 44 cases were stained (two 
cases had insufficient tissue available) all of which were neg-
ative for ALK expression. The majority of the patients was 
either current or former smokers (67, 74%) and had advanced 
NSCLC (TNM Stage III or IV) with a median overall sur-
vival time of 312.5 days (range 34–1961 days). Individuals 
who were former smokers (n = 48) had a better survival than 
current smokers (n = 24; p = 0.006; Supplementary Figure 1A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A789). Overall survival outcomes were improved in those 
with early stage disease (Stage I or II) compared with those 
with Stage III or Stage IV disease (p = 0.04; Supplementary 
Figure 1B, Supplemental Digital Content 2, http://links.lww.
com/JTO/A790).
Survival outcomes did not differ between patients diag-
nosed with ADC or SCC (p = 0.6). There was no difference 
in overall survival between men and women (p = 0.4), or 
between those with well-moderately differentiated and poorly 
differentiated SCCs (p = 0.6).
Mutation Detection by LungCarta 
and Verification
Ninety samples were tested of which there was com-
plete failure in only one due to poor quality DNA. The 
median success rate for an individual genotype in the panel 
was 95.5%. On initial screening with the LungCarta panel 39 
of 90 samples (43%), 47 definite mutations were identified. 
Equivocal mutations were defined as those with low mutant 
allele frequency (less than 10%), or poor quality spectra. An 
additional 56 equivocal mutations were detected in 40 cases 
(17 cases with definite mutation and 23 cases with equivocal 
only), resulting in 60/90 samples (67%) with either definite or 
equivocal mutations.
To verify mutations (definite and equivocal), a combina-
tion of pyrosequencing, Sanger sequencing, sequencing with 
the cobas EGFR Mutation Test, next-generation sequencing 
(TruSight Tumor Panel), and rescreening by the LungCarta 
panel was used. Using this detection limit, 31 of 56 equivo-
cal mutations with low allele frequency alterations (less than 
10%) were excluded from further testing (reported as negative 
787Copyright © 2015 by the International Association for the Study of Lung Cancer
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for mutations). Of the remaining 25 equivocal mutations fur-
ther testing confirmed eight mutations (Fig. 1). This yielded a 
final total of 55 confirmed mutations in 47 samples.
There were six samples with a mutation meeting the 
threshold to be defined as a definite mutation on primary 
screening for which the repeat (confirmation) MassARRAY 
spectrum was inconclusive. These included three mutations 
which had a low amplification yield from the amplification 
stage of the assay (EPHA5 p.E503K, STK11 p.F354L, and 
TP53 p.R248W). In addition, an equivocal spectrum was 
reported for the repeat EPHA3 p.D806N test and one repeat 
assay for an STK11 F354L mutation failed. Of note is that 
one TP53 mutation (p.R175H) identified on the original assay 
with two comutations (TP53 p.G245S, STK11 p.Y272Y) was 
not present on repeat assay although the comutations were 
detected.
To further verify the presence of TP53 mutations, we 
carried out immunohistochemical staining for p53 protein 
on 19 TP53-mutated samples (one of 20 samples harboring 
a TP53 mutation did not have sufficient tissue for IHC). It 
was important to determine the accuracy of the LungCarta 
genotyping for TP53 because more mutations were detected in 
this gene than any of the others genotyped. As TP53 is a large 
gene and multiple somatic mutations have been described, 
we decided to use IHC to determine protein levels as this is 
available as a standard diagnostic assay. Tumor staining was 
graded by a modified H score24,25 (maximum possible score 
300, Supplementary Figure 2, Supplemental Digital Content 
3, http://links.lww.com/JTO/A791) and the staining intensities 
were compared with those of 10 samples which were wild-
type for TP53.
TP53-mutated samples had either strong (3+) or moder-
ate (2+) staining intensities with H scores, which ranged from 
70 to 240 (mean 172 ± 46 SD, median 170). Only three of 19 
tumors had scores of 120 or less (70, 100, and 120). Although 
tumors reported negative for TP53 mutations after LungCarta 
screening tended to have lower staining intensities, the range 
was variable extending from 10 to 250 (mean 120 ± 87 SD, 
median 120). In fact, there were a number of these samples, 
which had significant staining (H score values of 90, 120, 120 
170, 210, and 250, respectively). We hypothesized that there 
were undetected mutations present which were responsible 
for these high intensity protein levels. As Sanger sequenc-
ing would have required more DNA than was available and 
is more labor intensive, the 10 cases wild-type for TP53 by 
LungCarta were screened by the TruSight tumor panel, which 
provides complete coverage of the TP53 sequence. The IHC 
H scores and the mutations detected by both panels from these 
10 samples are listed in Table 2. There were four cases with 
relatively high H scores (90, 120, 170, and 210) which had a 
missense mutation of TP53 on NGS. In addition, three tumors 
with low H scores of 12, 5, and 0 were found to harbor a TP53 
null mutation, frameshift mutation, and splice site mutation, 
respectively. All seven of these mutations were not included 
in the LungCarta panel. There were two samples with strong 
IHC staining (H scores 250 and 120) and one tumor with focal 
weak staining (H score 10) with no TP53 mutation. The pres-
ence of a missense mutation was strongly associated with any 
degree of moderate to strong IHC staining (H score greater 
than 20; p < 0.0001). NGS of these 10 selected cases did not 
detect any additional mutations that were already screened for 
in the LungCarta panel, indicating that there were no false 
negatives with the LungCarta assay.
Associations of Mutations identified 
by LungCarta with Clinicopathological 
Characteristics and NCC
A total 55 unequivocal mutations were detected in 47 of 
90 NSCLC tumor samples (52% of samples with at least one 
confirmed mutation). These included 22 alterations of TP53 
(24% of samples), 15 KRAS (17%), five EGFR (6%), three 
MET (3%), three PIK3CA (3%), two STK11 (2%), two NRF-2 
(2%), one EPHA5 (1%), one EPHA3 (1%), and one MAP2K1 
(1%). The individual mutations reported are listed in Table 3. 
A comparison of mutations reported in histological subgroups 
(Fig. 2) revealed that 22 of 44 SCCs (50%) harbored altera-
tions comprising TP53 (12, 27%), KRAS (three, 7%), PIK3CA 
(three, 7%), NRF-2 (two, 5%), STK11 (two, 5%), EPHA5 
(one, 2%), and EGFR (1, 2%), whereas 21 of 40 ADCs (52%) 
TABLE 1.  Clinicopathological Features of Patients and 
Samples, n = 90
Median age, years (range) 65 (41–85)
Sex, no. (%)
  Men 54 (60)
  Women 36 (40)
Smoking status, no. (%)
  Current smoker 24 (27)
  Former smoker 48 (53)
  Never smoker 2 (2)
  Unknown 16 (18)
Histology, no. (%)
  Adenocarcinoma 40 (44)
  Squamous cell carcinoma 44 (49)
  NOS 6 (7)
Type of specimen, no. (%)
  Primary; lung biopsies 72 (80)
   Wedge resection 1 (1)
   Lobectomies 2 (2)
  Metastatic; lymph nodes 7 (8)
   Pleural biopsies 4 (5)
   Pleural fluid 1 (1)
   Pericardial effusion 1 (1)
   Brain 1 (1)
   Soft tissue 1 (1)
Stagea, no. (%)
  I or II 6 (7)
  IIIA 18 (20)
  IIIB 18 (20)
  IV 31 (34)
  Unknown 17 (19)
aStaging by TNM 7th edition.49
NOS, not otherwise specified.
788 Copyright © 2015 by the International Association for the Study of Lung Cancer
Quinn et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 5, May 2015
were diagnosed with mutations (Table 3) including TP53 (six, 
15%), KRAS (ten, 25%), EGFR (three, 7.5%), MET (two, 
5%), MAP2K1 (one, 3%), and EPHA3 (one, 3%). There were 
six mutations (three TP53, two KRAS, and one MET muta-
tion/variant) reported in four of six cases finally classified as 
NSCLC NOS.
The most common alteration reported was in TP53 with 
22 mutations detected in 20 tumor samples, followed by KRAS 
(15 mutations in 15 samples) and EGFR (five mutations in 
four samples). KRAS mutations were associated with ADC 
histology (p = 0.03, Table 4). There was no apparent correla-
tion between age, sex, smoking history, SCC differentiation, 
or type of specimen (primary or metastatic) and the overall 
mutation status, the presence of TP53 or KRAS mutations 
(Table 4). Multiple mutations were reported in samples from 
six patients (6.7%), three of which included a KRAS muta-
tion (Supplementary Table 1, Supplemental Digital Content 
4, http://links.lww.com/JTO/A792). The presence of any 
detected mutations (p = 0.75), TP53 mutations (p = 0.22), or 
KRAS mutations (p = 0.64) detected by the LungCarta panel 
was not significantly associated with survival.
Thirty-four samples (38%) presented with necrosis 
accounting for up to 50% of the tissue content; however, this 
did not appear to interfere with subsequent amplification reac-
tions. The distribution of samples according to estimated NCC 
groups included 13 cases (14%) with 10–20%, 27 cases (30%) 
with 20–30%, 33 cases (37%) with 30–50%, and 17 cases 
(19%) with over 50% NCC. A total of 38 cases (including 
those originally with NCC below 10%) were macrodissected 
to increase the final NCC. The minimum NCC of samples in 
which mutations were detected was 10%. There was no sig-
nificant difference between the number of alterations reported 
in the different NCC groups (eight mutations in the 10–20% 
group, 13 mutations in the 20–30% group, 20 mutations in 
the 30–50% group, and six mutations diagnosed in the over 
50% group; p = 0.6) using χ2 analysis (Supplementary Figure 
3, Supplemental Digital Content 5, http://links.lww.com/JTO/
A793). The minimum number of neoplastic cells present, in 
samples where a mutation was detected, was estimated as 250.
DISCUSSION
We have screened 90 NSCLC tumor samples, the major-
ity of which were small biopsy specimens from patients with 
advanced stage disease, using the Sequenom LungCarta plat-
form. A multiplexed method such as the MassARRAY system 
allows the screening of multiple mutations in a single diagnos-
tic assay from one FFPET 5 μM section. Genetic alterations 
were confirmed in 52% of samples, (52% of ADCs and 50% 
of SCCs). Of the 55 mutations detected, 49 of these (89%) 
were confirmed by either an alternative method or a repeat 
screening by the LungCarta panel.
The TP53 tumor suppressor gene harbored the greatest 
number of mutations in both ADCs and SCCs, consistent with 
reported rates of TP53 mutations in 36 to 50% of ADCs26,27 
and in up to 80% of SCCs.28,29 Using p53 protein IHC, we 
determined that the majority of samples (16 of 19) with a 
TP53 mutation detected by LungCarta were strongly positive 
for p53 expression (H scores greater than 120), whereas the 
other three had moderate staining intensities. The LungCarta 
panel screens for 28 TP53 missense mutations that are often 
detected at a high frequency.30 However, our study revealed 
that six of 10 samples TP53 wild-type by LungCarta screen-
ing had significant staining intensities, and four of these were 
found by NGS to harbor missense mutations not represented 
on the LungCarta panel. There were four tumors wild-type for 
TP53 (by LungCarta screening) which had low H scores of 
less than or equal to 12. These included two carcinomas with 
TP53 nonsense and frameshift mutations detected by NGS, 
which would be expected to have an absent or reduced inten-
sity of staining due to a lack of discernible protein. The IHC 
staining intensity significantly correlated with detection of a 
TP53 missense mutation and may be a more practical screen-
ing tool for identification of p53 mutant NSCLC due to the 
large numbers of potential p53 mutations.
TABLE 2.  Comparison of p53 Immunohistochemistry H Scores with Mutations Detected by the TruSight Tumor Panel in 10 
Samples Negative for TP53 Mutation by the LungCarta Panel
Mutations Detected by 
LungCarta (Variant 
Frequency %) Mutations Detected by TruSight (Variant Frequency %)
TP53 IHC
H Scorea
KRAS G12A (75.0) KRAS G12A (73.1), APC Q1127b (4.3) 250
KRAS G12V (21.8) TP53 Q144P (23.8), KRAS G12V (29.4), FBXW7 R505L (14.1) 210
None TP53 G245C (12.2) 170
MET N375S (83.8) KRAS 
G12V (73.9)
TP53 G334V (70.8), KRAS G12V (77.1) 120
None KRAS G12C (3.3) 120
None TP53 H179R (23.2) 90
None TP53 E258b (69.8) 12
None None 10
None TP53 E298fs (41.5), PTEN V45fs (35.0), SRC V474M (4.0) 5
None TP53 c.673-1 splice (87.1) 0
aH score calculated from (area of tumor stained × intensity score 1+) + (area of tumor stained × intensity score 2+) + (area of tumor stained × intensity score 3+); maximum score 300.
bNull mutation.
IHC, immunohistochemistry.
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Mutations in KRAS were the second largest group of 
mutations identified in this analysis belonged to the KRAS 
gene. KRAS mutations were significantly associated with 
ADC histology and present in 25% of this subgroup, a find-
ing in keeping with elevated rates of KRAS mutations in lung 
ADCs from smoking populations with Caucasian ethnicity.31,32 
The EGFR mutant (E746_S752delinsV), finally classified as 
a squamous tumor, was poorly differentiated on H&E mor-
phology, had diffusely positive p40 staining and was negative 
for TTF-1 expression by IHC. EGFR mutations of SCCs are 
rare and occur at a rate of less than 5% within this morpho-
logical subgroup.33 Although EGFR-mutated SCCs are associ-
ated with a lower response rate (25% compared with 70% for 
ADC) to TKIs34,35 a multiplexed screening method applicable 
to all NSCLC could potentially identify these rare altera-
tions enabling the potential selection of patients with SCC 
for EGFR TKI therapy. One ADC was also found to harbor 
a mutation of the EPHA3 gene D806N which has previously 
been identified in a colorectal ADC.36 This is the first report 
of this mutation in lung ADC. Two poorly differentiated SCCs 
harbored mutations in the nuclear factor (erythroid-derived 
2)-like 2 gene (NRF2). In keeping with our findings, muta-
tions have been previously associated with squamous histol-
ogy from men with NSCLC.37
We have confirmed the presence of mutations in 47 
NSCLC tumor samples tested (52%), most of which are small 
biopsy samples. There was no apparent difference between 
the numbers of mutations detected in samples of differing 
NCC, including the group with the lowest tumor content, 
which was estimated as 10–20%. This reflects an estimated 
allele frequency detection limit of 5% for the LungCarta 
assay, and is comparable with the estimated allele frequency 
level that can be confidently detected by the SNaPshot system 
(approximately 5%).38 The median DNA content of samples 
assayed was 380.1 ng. Established diagnostic assays such as 
Pyrosequencing, Sanger sequencing, and the Cobas assay are 
restricted to the detection of a limited number of mutations 
per method. The DNA requirement for each of these tests 
(e.g., the Cobas EGFR Mutation Test is estimated to require 
a minimum of 150 ng of DNA) implies that an average lung 
TABLE 3.  Mutations detected by LungCarta panel in 90 NSCLC Tumor Samples
Gene
No. (%) of Samples Mutated
Total No. (%) of All 
Mutations Detected Mutations DetectedTotal ADC SCC NOS
TP53 20 (22.2) 6 (15) 12 (27) 2 (33) 22 (40) 4 x V157F, 2 x R158L, 2 x Y220C, 
2 x R248W, 2 x R273C, R158C, 
R158P, R175H, R175L, G245S, 
G245V, R248L, R249M, R273H, 
R282W
KRAS 15 (17) 10 (25) 3 (7) 1 (17) 15 (27.2) 6 x Gly12C, 6 x G12V, G12A, 
G13D, Q61H
EGFR 4 (4.4) 3 (7.5) 1 (2) 0 (0) 5 (9) G746_S752delinsV, V774M, 
G746_A750del, L858R
MET 3 (3.3) 2 (5) 0 (0) 1 (17) 3 (5.5) 3 x N375Sa
PIK3CA 3 (3.3) 0 (0) 3 (7) 0 (0) 3 (5.5) 2 x E545K, H1047R
STK11 2 (2.2) 0 (0) 2 (5) 0 (0) 2 (3.6) Y272Yb, F354L
NRF-2 2 (2.2) 0 (0) 2 (5) 0 (0) 2 (3.6) R34Q, D29H
MAP2K1 1 (1.1) 1 (3) 0 (0) 0 (0) 1 (1.8) Q56P
EPHA5 1 (1.1) 0 (0) 1 (2) 0 (0) 1 (1.8) E503K
EPHA3 1 (1.1) 1 (3) 0 (0) 0 (0) 1 (1.8) D806N
aThe N375S variant has been reported as a germline missense substitution.50
bThe Y272Y variant has been reported as a silent substitution c.816C>T.51
NSCLC, non–small-cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NOS, not otherwise specified.
FIGURE 2.  Mutations detected by LungCarta panel in  
(A) squamous cell carcinomas, n = 44 and (B) adenocarcinomas, 
n = 40 (six additional mutations were confirmed in four of six 
cases classified as non–small-cell lung cancer not otherwise 
specified, not shown).
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biopsy will have insufficient material using a combination of 
methods to provide a profile of mutations.
The advent of targeted NGS panels promises the capac-
ity to diagnose variants with allele frequencies as low as 
1%.39,40 However, caution must be applied in the separation of 
amplification-derived artifacts from true low frequency vari-
ants, and the appropriate limits of detection must be robustly 
defined for use in a clinical diagnostic setting.41 The major-
ity of published NGS studies profiling tumor samples have 
sampled fresh-frozen tissue from primary resection speci-
mens with relatively high NCC levels of at least 50%.26,29 In 
this study, we observed that to obtain an adequate DNA yield 
for NGS it was necessary to use increased number of tumor 
sections of greater thickness (5 × 10 μM) compared with that 
required for the Sequenom assay (1 × 5 μM). This seems to 
be in agreement with data from Tuononen et al. who reported 
a high concordance rate (96.3–100%) between mutations 
detected by real time PCR and NGS. This group extracted 
DNA from 2/3 × 16 μM sections with a NCC of at least 20%, 
and used 2–3 μg of DNA for sequencing with the Illumina 
HISeq2000 sequencer.42 Similarly, a recent report by de 
Biase et al. describes the application of 454 NGS to cytology 
samples using 6 × 10 μM macrodissected sections. Another 
strategy employed to increase the likelihood of detecting low 
frequency variants in cytology samples and biopsies with 
NCCs of 5–10% has been to use a twostep DNA amplification 
protocol.40 This group also used 454 NGS and noted a positive 
correlation between NCC and allele frequency. Ultimately the 
requirement of a greater number of thicker sections contain-
ing viable tumor is a challenge facing diagnostic pathology 
laboratories that may not always be possible to fulfill, but can 
potentially be met by the implementation of strict algorithms 
that balance the demands of diagnostic molecular testing.13
The majority of previous studies employing systematic 
testing or multiplexed methods have relied on tumor resection 
samples from ADCs (Supplementary Table 2, Supplemental 
Digital Content 6, http://links.lww.com/JTO/A794). Our 
rate of detection in 52% of cases is comparable with those 
reported in diagnostic mutation studies, and confirms that 
small biopsy samples are a valid option for high throughput 
assays.43,44 Maeng et al.44 screened for mutations in biopsy 
samples obtained with radiological intervention, bronchos-
copy or endobronchial ultrasound guidance and reported 
alterations in 67% of cases. This relatively high mutation 
rate may be explained by the fact that DNA was extracted 
from fresh-frozen tissues, avoiding the risk of artifacts that 
may arise from formalin-fixation. Furthermore, screening of 
specific oncogenes in selected populations, such as ADCs 
from Asian never smokers, will result in a higher mutation 
detection rate (Supplementary Table 2, Supplemental Digital 
Content 6, http://links.lww.com/JTO/A794).45–47 We have 
also confirmed the presence of multiple alterations in 6.7% 
of tumors screened, a value in agreement with earlier reports 
such as the percentages of cases with synchronous mutations 
reported by Yip et al.17 (8.8% screening with the Sequenom 
OncoCarta panel) and Okamoto et al.43 (10.2% screening 
with the Sequenom LungCarta panel; Supplementary Table 
2, Supplemental Digital Content 6, http://links.lww.com/
JTO/A794). This highlights the importance of validating high 
throughput platforms that not only facilitate the optimization 
of individual treatment regimens but also enable the predic-
tion of resistance to therapies that arise secondary to coexist-
ing alterations.48
In our laboratory, the diagnostic turnaround time for the 
LungCarta assay is 10 working days, with a cost equivalent to 
approximately two single-plex somatic mutation assays. This 
TABLE 4.  Comparison of Mutated Samples with Clinicopathological Factors
Total No. Mutated Samples (%) TP53-Mutated Samples (%) KRAS-Mutated Samples (%)
Pos. Neg. p Pos. Neg. p Pos. Neg. p
Median age at diagnosis 65.15 66.48 0.678 68.00 65.27 0.946 63.54 65.99 0.536
Sex
  Men 29 (53) 26 (47) 0.904 12 (22) 43 (78) 0.908 6 (11) 49 (89) 0.066
  Women 18 (51) 17 (49) 8 (23) 27 (77) 9 (26) 26 (74)
Smoking history
  Current/former 37 (51) 35 (49) 0.752 18 (25) 54 (75) 0.205 10 (14) 62 (86) 0.157
  Unknown/never 10 (56) 8 (44) 2 (11) 16 (89) 5 (28) 13 (72)
Histologya
  ADC 21 (53) 19 (47) 0.819 6 (15) 34 (85) 0.171 10 (25) 30 (75) 0.0214
 SCC 22 (50) 22 (50) 12 (27) 32 (73) 3 (7) 41 (93)
SCC differentiation
  Low-grade SCC 9 (41) 13 (59) 0.228 7 (32) 15 (68) 0.498 N/A N/A
  High-grade SCC 13 (59) 9 (41) 5 (23) 17 (77)
Type of specimen
  Primary 40 (53) 35 (47) 0.637 17 (23) 58 (77) 0.821 11 (51) 64 (51) 0.255
  Metastatic 7 (47) 8 (53) 3 (20) 12 (80) 4 (51) 11 (51)
aData on six NSCLC NOS samples were not included.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; N/A, not applicable; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified.
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is, therefore, cheaper than undertaking analysis on three or 
more genes individually. In summary, we report the Sequenom 
LungCarta panel as a clinically useful diagnostic screening 
test for small biopsy samples of NSCLC. This assay can con-
fidently detect mutations at NCC levels of 10% and above, 
using a single 5 μM section.
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